natgillin/translations-raw huggingface dataset:
A compound of formula (1) as defined in claim 7, wherein R2 is het2, and het2 is selected from the group consisting of 5 or 6 membered monocyclic heteroaromatic groups containing 1 or 2 nitrogen atoms. 
Spoj formule (1) u skladu s patentnim zahtjevom 7, naznačen time što R2 je het2, gdje het2 se bira iz skupine koju čine 5- ili 6-eročlane monocikličke heteroaromatske skupine s 1 ili 2 atoma dušika.
A compound of formula (1) as defined in claim 9, wherein R2 is a pyridazinyl group. 
Spoj formule (1) u skladu s patentnim zahtjevom 9, naznačen time što R2 je piridazinilna skupina.
A compound of formula (1) as defined in claim 11, wherein R1 and R2 form together with the N atom to which they are attached a morpholinyl group. 
Spoj formule (1) u skladu s patentnim zahtjevom 11, naznačen time što R1 i R2, zajedno s atomom dušika na kojeg su vezani, tvore morfolinilnu skupinu.
A compound of formula (1) as defined in claim 13, wherein R3 and R4 are selected Independently from hydrogen, methyl and ethyl, or R3 and R4 form together with the N atom to which they are attached a pyrrolidinyl, piperidinyl, piperazinyl or azetidinyl ring, each pyrrolidinyl, piperidinyl, piperazinyl and azetidinyl ring being optionally methyl substituted. 
Spoj formule (1) u skladu s patentnim zahtjevom 13, naznačen time što R3 i R4 se neovisno bira između vodika, metila i etila, ili R3 i R4, zajedno s atomom dušika na kojeg su vezani, tvore pirolidinilni, piperidinilni, piperazinilni ili azetidinilni prsten, gdje svaki od pirolidinilnog, piperidinilnog, piperazinilnog i azetidinilnog prstena je izborno supstituiran metilom.
A compound of formula (1) as defined in claim 19, wherein R7 and R8 form together with the N atom to which they are attached a morpholinyl or oxazepanyl group. 
Spoj formule (1) u skladu s patentnim zahtjevom 19, naznačen time što R7 i R8, zajedno s atomom dušika na kojeg su vezani, tvore morfolinilnu ili oksazepanilnu skupinu.
A compound of formula (1) as defined in claim 19, wherein R7 and R8 form together with the N atom to which they are attached a 4-, 5- or 6-membered saturated heterocycle, optionally substituted by one or two (C1-C4)alkyl groups. 
Spoj formule (1) u skladu s patentnim zahtjevom 19, naznačen time što R7 i R8, zajedno s atomom dušika na kojeg su vezani, tvore 4-, 5- ili 6-eročlani zasićeni heterocikl, izborno supstituiran s jednom ili dvije (C1-C4)alkilne skupine.
A compound of formula (1) as defined in claim 21, wherein the saturated heterocycle is a pyrrolidinyl group, optionally substituted by one or two methyl groups. 
Spoj formule (1) u skladu s patentnim zahtjevom 21, naznačen time što zasićeni heterocikl je pirolidinilna skupina, izborno supstituirana s jednom ili dvije metilne skupine.
A compound of formula (1) as defined in claim 25, wherein R9 is isopropyl or cyclobutyl. 
Spoj formule (1) u skladu s patentnim zahtjevom 25, naznačen time što R9 je izopropil ili ciklobutil.
The use of a compound of the formula (1) according to claim 30 wherein the cognition deficiency disease is Alzheimer's disease or mild cognitive impairment. 
Upotreba spoja formule (1) u skladu s patentnim zahtjevom 30, naznačena time što bolest spoznajne deficijencije je Alzheimerova bolest ili blagi kognitivni poremećaj.
Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; 
prsten C je karbociklil ili heterociklil; pri čemu ako navedeni heterociklil sadrži -NH- skupinu taj dušik može biti opcijski supstituiran sa skupinom odabranom od R17;
n is 1 or 2; wherein the values of R5 may be the same or different; 
n je 1 ili 2; pri čemu vrijednosti R5 mogu biti iste ili različite;
A is a direct bond; 
A je a direktna veza;
A compound of formula (I): selected from: 
Spoj formule (I): [image] odabran od:
Process e) reacting a compound of formula (VII): wherein L is a displaceable group; with an amine of formula (VIII): wherein Pg is a nitrogen protecting group; 
postupak e) reakcijom spoja formule (VII): [image] pri čemu L je skupina koja mijenja mjesto; sa aminom formule (VIII): [image] pri čemu Pg je dušikova zaštitna skupina;
Process f) reacting a compound of formula (IX): with a compound of formula (X): wherein L is a displaceable group; 
postupak f) reakcijom spoja formule (IX): [image] sa spojem formule (X): [image] pri čemu L je skupina koja mijenja mjesto;
and thereafter if necessary: 
i nakon toga ako je potrebno:
converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups, iii) forming a pharmaceutically acceptable salt. 
pretvaranja spoja formule (I) u drugi spoj formule (I); ii) uklanjanja bilo koje zaštitne skupine iii) formiranja farmaceutski prihvatljive soli.
A product comprising (a) a PDE4 inhibitor as defined in any one of claims 1 and 3 to 6 and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease which responds to M3 antagonism. 
Proizvedeni lijek, naznačen time, da sadrži (a) inhibitor PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6 i (b) antagonist muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2, u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u liječenju bolesnika koji boluje od ili je osjetljiv na bolest dišnih putova koja reagira na M3 antagonizam.
A method for aging an alcoholic liquid, in which the alcoholic liquid is esterified in the presence of an esterification catalyst, characterized in that said alcoholic liquid is esterified in supercritical carbon dioxide so as to reduce the time required for aging the alcoholic liquid. 
Postupak dozrijevanja alkoholne tekućine, u kojem se alkoholnu tekućinu esterificira u prisutnosti katalizatora esterifikacije, naznačen time što navedenu alkoholnu tekućinu se esterificira u superkritičnom ugljičnom dioksidu, kako bi se skratilo vrijeme potrebno za dozrijevanje alkoholne tekućine.
The method of claim 2, wherein said supercritical trough is filled with distillation packing, and said esterification catalyst in said catalyst trough is a lipase. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što se u navedeno superkritično korito se stavi destilacijskim paket, a navedeni katalizator esterifikacije u navedenom katalizatorskom koritu je lipaza.
a supercritical trough including a trough body, a material supply device, and a supercritical fluid supply device, wherein said material supply device supplies a material to said trough body, and said supercritical fluid supply device supplies a supercritical fluid to said trough body, while said trough body holds the material and the supercritical fluid that have been supplied thereto, and allows the material and the supercritical fluid to form an evenly-distributed solution; and a catalyst trough including a trough body and a product drain device; wherein said trough body holds a catalyst therein, and said product drain device is for draining a product away from said trough body of said catalyst trough; said catalyst trough and said supercritical trough are connected so as to allow said evenly-distributed solution to come into contact with said catalyst and undergo catalytic reactions. 
superkritičnog korita, uključujući trup korita, uređaj za dobavu materijala i uređaj za dobavu superkritičnog fluida, gdje navedeni uređaj za dobavu materijala dobavlja materijal u navedeni trup korita, gdje navedeni uređaj za dobavu superkritičnog fluida dobavlja superkritični fluid u navedeni trup korita, dok navedeni trup korita sadrži materijal i superkritični fluid kojima je napunjen, što omogućuje da materijal i superkritični fluid tvore homogenu otopinu; i katalizatorskog korita, uključujući trup korita i uređaj za uzimanje proizvoda; gdje navedeni trup korita sadrži katalizator, a navedeni uređaj za uzimanje proizvoda služi za utimanje proizvoda iz navedenog trupa korita navedenog katalizatorskog korita; navedeno katalizatorsko korito i navedeno superkritično korito su povezana, tako da se omogući da navedena homogena otopina dođe u kontakt s navedenim katalizatorom, te da dođe do katalitičkih reakcija.
The apparatus of claim 8, wherein said supercritical fluid is supercritical carbon dioxide. 
Uređaj u skladu s patentnim zahtjevom 8, naznačen time što navedeni superkritični fluid je superkritični ugljični dioksid.
The apparatus of claim 8 further comprising a temperature control device for controlling the temperature in said supercritical trough. 
Uređaj u skladu s patentnim zahtjevom 8, naznačen time što dodatno sadrži uređaj za kontrolu temperature, radi kontroliranja temperature u navedenom superkritičnom koritu.
A product comprising (a) a β2 agonist as defined in claim 1 or 3 and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease as defined in claim 7 or 8. 
Proizvedeni lijek, naznačen time, da sadrži (a) inhibitor PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6 i (b) antagonist muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2, u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u liječenju bolesnika koji boluje od ili je osjetljiv na bolest dišnih putova koja reagira na M3 antagonizam.
is a single bond or a lower alkylene group, wherein one or two or more methylene groups constituting the lower alkylene group may be independently replaced by an oxygen atom or a carbonyl group, and/or substituted by a lower alkyl group; 
je jednostruka veza ili C1-6alkilen skupina, gdje jedna ili više metilenskih skupina koje tvore alkilensku skupinu mogu nezavisno jedna od druge biti zamijenjene atomom kisika, sumpora, karbonilnom, sulfinilnom ili sulfonilnom skupinom, i/ili supstituirane atomom halogena, cijano, hidroksilnom ili C1-6alkil skupinom;
is a single bond or a lower alkylene group, wherein one or two or more methylene groups constituting the lower alkylene group may be independently replaced by an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group or a sulfonyl group, and/or substituted by a halogen atom, a cyano group, a hydroxyl group or a lower alkyl group; 
d i R1e su nezavisno jedan od drugog atom vodika, halogena, cijano skupina, hidroksilna skupina, C1-6alkil skupina ili hidroksil-C1-6alkil skupina, ili zajedno tvore C1-6alkilen skupinu gdje jedna ili više metilenskih skupina koje tvore alkilensku skupinu mogu nezavisno jedna od druge biti zamijenjene atomom kisika, sumpora, sulfinilnom, sulfonilnom, karbonilnom, vinilenskom ili of -N(R1f)- skupinom, i/ili supstituirane hidroksilnom ili C1-6alkil skupinom;
is a nitrogen atom, or is a methine group optionally substituted by a halogen atom, a hydroxyl group, a lower alkyl group or a hydroxy-lower alkyl group; 
je atom dušika, ili je metinska skupina koja po izboru može biti supstituirana atomom halogena, hidroksilnom, C1-6alkil ili hidroksi-C1-6alkil skupinom;
R1a and R1b are independently a hydrogen atom, a lower alkyl group or a hydroxy-lower alkyl group, or together form a lower alkylene group wherein one or two or more methylene groups constituting the lower alkylene group may be independently replaced by an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a vinylene group or a group of -N(R1c)-, and/or substituted by a hydroxyl group or a lower alkyl group; 
g i R1h su nezavisno jedan od drugog atom vodika, halogena, cijano, hidroksilna, C1-6alkil, C1-6alkoksi-C1-6alkil, C2-7alkanoil, C2-7alkoksikarbonil ili C1-6alkilsulfonil skupina, ili zajedno tvore C1-6alkilen skupina, gdje jedna ili više metilenskih skupina koje tvore alkilensku skupinu mogu nezavisno jedna od druge biti zamijenjene atomom kisika, sumpora, sulfinilnom, sulfonilnom, karbonilnom ili of -N(R1i)- skupinom, i/ili supstituirane atomom halogena ili C1-6alkil skupinom;
is a methine group optionally substituted by a hydroxyl group or a lower alkyl group, Q3 is a single bond, and R1d and R1e are independently a hydrogen atom or a lower alkyl group; 
je metin skupina po izboru supstituirana hidroksil ili C1-6alkil skupinom, Q3 je jednostruka veza, a R1d i R1e su nezavisno jedan od drugog atoma vodika ili C1-6alkil skupina; ili
A combined preparation for simultaneous, separate, or sequential administration in the treatment of cancer, comprising following two separate preparations (a) and (b): 
Kombinirani pripravak za istodobnu, odvojenu ili uzastopnu primjenu u liječenju raka, naznačen time što sadrži sljedeća dva odvojena pripravka (a) i (b):
the anticancer camptothecin derivatives are irinotecan, topotecan, and camptothecin; 
derivati kamptotecina su irinotekan, topotekan i kamptotecin;
and B2 are adjacent atoms in HET1 which are independently selected from a group consisting of carbon and nitrogen; 
i B2 su susjedni atomi u HET1, koji se neovisno biraju iz grupe koju čine ugljik i dušik;
The compound of claim 1, wherein HET1 is a 5 membered heterocyclic aromatic ring. 
Spoj prema Zahtjevu 1, naznačen time, što HET1 predstavlja neki peteročlani heterociklični aromatični prsten.
A process for forming the compound of formula I as defined in claim 1, comprising a step of reacting a compound of formula IV with dimethoxymethyl-dimethylamine and hydrazine or a substituted hydrazine. 
Postupak za dobivanje spoja formule I, definiranog u Zahtjevu 1, koji se sastoji od koraka reagiranja spoja formule IV [image] s dimetoksimeti-dimetilaminom i hidrazinom, ili nekim supstituiranim hidrazinom.
A pharmaceutical composition comprising a compound of formula I as defined in claim 1 or claim 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija sadrži spoj formule I, definiran u Zahtjevu 1 ili u Zahtjevu 13, ili njegovu farmaceutski prihvatljivu sol, i neki farmaceutski prihvatljiv nosač.
A compound according to claim 1 or claim 13, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder selected from psychotic disorders, delusional disorders and drug induced psychosis; anxiety disorders, movement disorders, mood disorders, obesity, and neurodegenerative disorders. 
Spoj prema Zahtjevu 1 ili Zahtjevu 13, ili njegova farmaceutski prihvatljiva sol, koji se upotrebljava u tretmanu nekog poremećaja koji se bira između psihotičnih poremećaja, deluzijskih poremećaja i psihoze izazvane lijekom; poremećaja anksioznosti, poremećaja kretanja, poremećaja raspoloženja, pretilnosti i neurodegenerativnih poremećaja.
-X-Y- together represents a group of the formula: 
-X-Y- zajedno predstavlja skupinu formule:
A compound according to claim 13, wherein the medicament is a medicament for treatment of metabolic syndrome, type II diabetes, obesity or atherosclerosis. 
Spoj prema zahtjevu 13, naznačen time da lijek je lijek za liječenje metaboličkih sindroma, dijabetesa tipa II, pretilosti ili ateroskleroze.
reaction of a compound of Formula (2) with a compound of Formula (3): 
reakciju spoja formule (2) sa spojem formule (3): [image]
reaction of a compound of Formula (8) with a compound of Formula (9): wherein X" is a leaving group; or 
reakciju spoja formule (8) sa spojem formule (9): [image] pri čemu X" je odlazna skupina; ili
reaction of a compound of Formula (10) with a compound of Formula (11): wherein X"' is a leaving group; 
reakciju spoja formule (10) sa spojem formule (11): [image] pri čemu X"' je odlazna skupina;
and thereafter if necessary or desirable: 
i nakon toga ako je potrebno ili poželjno:
converting a compound of the formula (1) into another compound of the formula (1); 
pretvaranja spoja formule (1) u drugi spoj formule (1);
and R9 taken together with nitrogen to which they are attached form a non- aromatic heterocyclic ring containing 2 - 6 carbon atoms which is: 
i R9, uzeti zajedno s dušikom na kojeg su vezani, tvore nearomatski heterociklički prsten s 2-6 atoma ugljika koji je:
is hydrogen or a hydroxyl protecting group; 
je vodik ili zaštitna skupina za hidroksil;
A compound of Formula (I) according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R8 and R9 taken together with nitrogen to which they are attached form a C5-7 membered saturated non-aromatic heterocyclic ring. 
Spoj Formule (I) u skladu s bilo kojim od patentnih zahtjeva 1-5, ili njegova farmaceutski prihvatljiva sol, naznačen time što R8 i R9, uzeti zajedno s dušikom na kojeg su vezani, tvore C5-7-eročlani zasićen nearomatski heterociklički prsten.
reacting a compound of formula (VIII) wherein n is an integer from 1 to 7 with a compound of formula HNR8aR9a (V), wherein R8a and R9a are R8 and R9 as defined in claim 1 or groups convertible to R8 and R9, to produce a compound of formual (I) wherein R1 is -O-(CH2)nNR8R9 and n is an integer from 1 to 8; 
reakcije spoja formule (VIII), gdje n je cijeli broj od 1 do 7, sa spojem formule HNR8aR9a (V), gdje R8a i R9a su R8 i R9, kao što je definirano u patentnom zahtjevu 1, ili sa skupinama koje se može prevesti u R8 i R9, kako bi se dobilo spoj formule (I), gdje R1 je -O-(CH2)nNR8R9, a n je cijeli broj od 1 do 8;
removal of the protecting group R2, 
uklanjanja zaštitne skupine R2,
conversion of the resultant compound of formula (I) into a pharmaceutically acceptable salt thereof. 
prevođenja dobivenog spoja formule (I) u njegovu farmaceutski prihvatljivu sol.
Use of a compound of Formula (I) according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of an inflammatory disease, disorder or condition characterized by or associated with an undesirable inflammatory immune response, or an excessive secretion of TNF-a, IL-1, IL-6 and IL-8; or for the treatment of an inflammatory condition or immune or anaphylactic disorder associated with infiltration of leukocytes into inflamed tissue. 
Upotreba spoja Formule (I) u skladu s bilo kojim od patentnih zahtjeva 1-10, ili njegove farmaceutski prihvatljive soli, gdje je navedeni spoj namijenjen proizvodnji medikamenta za liječenje upalne bolesti, poremećaja ili stanja, naznačenih time što su ili su povezani s nepoželjnim upalnim imunosnim odgovorom ili prekomjernim lučenjem TNF-a, IL-1, IL-6 i IL-8; ili za liječenje upalnog stanja ili imunosnog ili anafilaktičkog poremećaja povezanog s infiltracijom leukocita u upaljeno tkivo.
Use according to claim 14, wherein the inflammatory condition or immune disorder is selected from the group consisting of asthma, COPD, diffuse panbronchiolitis, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, chronic bronchitis and cystic fibrosis. 
Upotreba u skladu s patentnim zahtjevom 14, naznačena time što upalno stanje ili imunosni poremećaj se bira iz skupine koju čine astma, COPD, difuzni panbronhiolitis, sindrom dišnog distresa kod odraslih, upalna bolest crijeva, Crohnova bolest, kronični bronhitis i cistična fibroza.
Use according to claim 14, wherein the inflammatory condition or immune disorder is selected from the group consisting of asthma, adult respiratory distress syndrome, bronchitis, bronchiectasis, bronchiolitis obliterans, cystic fibrosis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, osteomyelitis, sinusitis, nasal polyps, gouty arthritis, uveitis, conjunctivitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, distal proctitis, psoriasis, eczema, dermatitis, acne, coronary infarct damage, chronic inflammation, endotoxin shock, chronic sinusitis, pulmonary fibrosis, diffuse panbronchiolitis, and smooth muscle proliferation disorders. 
Upotreba u skladu s patentnim zahtjevom 14, naznačena time što upalno stanje ili imunosni poremećaj se bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, bronhitis, bronhiektazija, obliterantni bronhiolitis, cistična fibroza, reumatoidni artritis, reumatoidni spondilitis, osteoartritis, osteomijelitis, sinusitis, nosni polipi, gihtični artritis, uveitis, konjunktivitis, upalna bolest crijeva, Crohnova bolest, ulcerozni kolitis, distalni proktitis, psorijaza, ekzem, dermatitis, akne, ozljeda zbog koronarnog infarkta, kronična upala, endotoksinski šok, kronični sinusitis, plućna fibroza, difuzni panbronhiolitis, te poremećaji proliferacije glatkih mišića.
A compound of Formula (I) according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof, for use in the treatment of an inflammatory disease, disorder or condition characterized by or associated with an undesirable inflammatory immune response, or an excessive secretion of TNF-a, IL-1, IL-6 and IL-8; or for use in the treatment of an inflammatory condition or immune or anaphylactic disorder associated with infiltration of leukocytes into inflamed tissue. 
Spoj Formule (I) u skladu s bilo kojim od patentnih zahtjeva 1-10, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u liječenju upalne bolesti, poremećaja ili stanja, naznačenih time što su ili su povezani s nepoželjnim upalnim imunosnim odgovorom ili prekomjernim lučenjem TNF-a, IL-1, IL-6 i IL-8; ili naznačen time što je namijenjen upotrebi u liječenju upalnog stanja ili imunosnog ili anafilaktičkog poremećaja povezanog s infiltracijom leukocita u upaljeno tkivo.
A compound of Formula (I) according to claim 19, or a pharmaceutically acceptable salt thereof, wherein the inflammatory condition or immune disorder is selected from the group consisting of asthma, COPD, diffuse panbronchiolitis, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, chronic bronchitis and cystic fibrosis. 
Spoj Formule (I) u skladu s patentnim zahtjevom 19, ili njegova farmaceutski prihvatljiva sol, naznačena time što upalno stanje ili imunosni poremećaj se bira iz skupine koju čine astma, COPD, difuzni panbronhiolitis, sindrom dišnog distresa kod odraslih, upalna bolest crijeva, Crohnova bolest, kronični bronhitis i cistična fibroza.
A compound of Formula (I) according to claim 19, or a pharmaceutically acceptable salt thereof, wherein the inflammatory condition or immune disorder is selected from the group consisting of asthma, adult respiratory distress syndrome, bronchitis, bronchiectasis, bronchiolitis obliterans, cystic fibrosis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, osteomyelitis, sinusitis, nasal polyps, gouty arthritis, uveitis, conjunctivitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, distal proctitis, psoriasis, eczema, dermatitis, acne, coronary infarct damage, chronic inflammation, endotoxin shock, chronic sinusitis, pulmonary fibrosis, diffuse panbronchiolitis, and smooth muscle proliferation disorders. 
Spoj Formule (I) u skladu s patentnim zahtjevom 19, ili njegova farmaceutski prihvatljiva sol, naznačena time što upalno stanje ili imunosni poremećaj se bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, bronhitis, bronhiektazija, obliterantni bronhiolitis, cistična fibroza, reumatoidni artritis, reumatoidni spondilitis, osteoartritis, osteomijelitis, sinusitis, nosni polipi, gihtični artritis, uveitis, konjunktivitis, upalna bolest crijeva, Crohnova bolest, ulcerozni kolitis, distalni proktitis, psorijaza, ekzem, dermatitis, akne, ozljeda zbog koronarnog infarkta, kronična upala, endotoksinski šok, kronični sinusitis, plućna fibroza, difuzni panbronhiolitis, te poremećaji proliferacije glatkih mišića.
A compound of Formula (I) according to claim 19, or a pharmaceutically acceptable salt thereof, wherein the inflammatory condition or immune disorder is COPD. 
Spoj Formule (I) u skladu s patentnim zahtjevom 19, ili njegova farmaceutski prihvatljiva sol, naznačena time što upalno stanje ili imunosni poremećaj je COPD.